Sign Out
Pharmacotherapeutic group: Testosterone-5-alpha-reductase inhibitors.
Pharmacology: Pharmacodynamics: Dutasteride reduces circulating levels of dihydrotestosterone (DHT) by inhibiting both type 1 and type 2, 5α-reductase isoenzymes which are responsible for the conversion of testosterone to DHT.
Pharmacokinetics: Dutasteride is absorbed from the gastrointestinal tract, reaching a peak serum concentration of 1 to 3 hours, with bioavailability of about 60%. It is highly bound to plasma proteins. Dutasteride is metabolised by the cytochrome P450 isoenzymes CYP3A5, and most of a dose is excreted as metabolites in the feces. At steady state, the elimination half-life is about 3 to 5 weeks.
